EPISODE · Oct 17, 2022 · 2 MIN
WHY ARE MOST CHILDREN AND ADULTS SAFE FROM COVID?
from The Highwire with Del Bigtree · host The Highwire with Del Bigtree
World-renowned virologist, Geert Vanden Bossche, explains how innate antibodies differ from naturally acquired antibodies, thereby protecting children and healthy adults from developing serious disease associated with Covid-19.Get the Facts:https://www.frontiersin.org/articles/10.3389/fimmu.2020.02139/fullhttps://www.frontiersin.org/articles/10.3389/fimmu.2017.00872/fullhttps://www.nih.gov/news-events/nih-research-matters/lasting-immunity-found-after-recovery-covid-19?fbclid=IwAR2WENPwM1tZfnM7lNrFNAT6zkdxGieo1i9Ay5NsCEzE6MSDoOOk8qlxGrU%20https://www.nih.gov/news-events/nih-research-matters/lasting-immunity-found-after-recovery-covid-19?fbclid=IwAR2WENPwM1tZfnM7lNrFNAT6zkdxGieo1i9Ay5NsCEzE6MSDoOOk8qlxGrU#GetFactsinated #GVB #InnateAntibodies #Covid19Become a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.
What this episode covers
World-renowned virologist, Geert Vanden Bossche, explains how innate antibodies differ from naturally acquired antibodies, thereby protecting children and healthy adults from developing serious disease associated with Covid-19.Get the Facts:https://www.frontiersin.org/articles/10.3389/fimmu.2020.02139/fullhttps://www.frontiersin.org/articles/10.3389/fimmu.2017.00872/fullhttps://www.nih.gov/news-events/nih-research-matters/lasting-immunity-found-after-recovery-covid-19?fbclid=IwAR2WENPwM1tZfnM7lNrFNAT6zkdxGieo1i9Ay5NsCEzE6MSDoOOk8qlxGrU%20https://www.nih.gov/news-events/nih-research-matters/lasting-immunity-found-after-recovery-covid-19?fbclid=IwAR2WENPwM1tZfnM7lNrFNAT6zkdxGieo1i9Ay5NsCEzE6MSDoOOk8qlxGrU#GetFactsinated #GVB #InnateAntibodies #Covid19Become a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.
NOW PLAYING
WHY ARE MOST CHILDREN AND ADULTS SAFE FROM COVID?
No transcript for this episode yet
Similar Episodes
Dec 5, 2025 ·50m
Oct 9, 2025 ·33m
Oct 3, 2025 ·40m
Sep 11, 2025 ·31m
Aug 27, 2025 ·39m
Aug 18, 2025 ·54m